DASOLAMPANEL ETIBUTIL TOSYLATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C23H32ClN5O3.C7H8O3S
Molecular Weight	634.187
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of DASOLAMPANEL ETIBUTIL TOSYLATE

Structure Search

SMILES

CC1=CC=C(C=C1)S(O)(=O)=O.[H][C@@]23CC[C@@H](C[C@]2([H])C[C@H](NC3)C(=O)OCC(CC)CC)OC4=C(C5=NN=NN5)C(Cl)=CC=C4

InChI

InChIKey=WLTMCPAAIJIZKG-BVNPURGCSA-N

InChI=1S/C23H32ClN5O3.C7H8O3S/c1-3-14(4-2)13-31-23(30)19-11-16-10-17(9-8-15(16)12-25-19)32-20-7-5-6-18(24)21(20)22-26-28-29-27-22;1-6-2-4-7(5-3-6)11(8,9)10/h5-7,14-17,19,25H,3-4,8-13H2,1-2H3,(H,26,27,28,29);2-5H,1H3,(H,8,9,10)/t15-,16+,17-,19-;/m0./s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24631589 | https://www.ncbi.nlm.nih.gov/pubmed/23110368 | https://www.ncbi.nlm.nih.gov/pubmed/24140446

Dasolampanel (NGX-426) is an orally available competitive antagonist of the AMPA and kainate receptors. The dug originated at Eli Lilly and Horizon Pharma and was developed for the treatment of migraine and neuropathic pain. Dasalompanel was reduced capsaicin-induced pain and hyperalgesia in human volunteers but failed to achieve positive results in phase 2 clinical trials in patients with pain due to osteoarthritis of the knee and diabetic peripheral neuropathic pain.

Originator

Approval Year

Patents

Name

Type

Language

DASOLAMPANEL ETIBUTIL TOSYLATE

Official Name

English

DASOLAMPANEL ETIBUTIL TOSYLATE [USAN]

Common Name

English

3-ISOQUINOLINECARBOXYLIC ACID, 6-(3-CHLORO-2-(1H-TETRAZOL-5-YL)PHENOXY)DECAHYDRO-, 2-ETHYLBUTYL ESTER, (3S,4AS,6S,8AR)-, MONO(4-METHYLBENZENESULFONATE)

Common Name

English

Code System Code Type Description

FDA UNII

9QY59JQF76